A phase II trial of the Src-kinase inhibitor saracatinib after four cycles of chemotherapy for patients with extensive stage small cell lung cancer: NCCTG trial N-0621.
about
New and emerging developments in extensive-stage small cell lung cancer therapeuticsSrc inhibitors act through different mechanisms in Non-Small Cell Lung Cancer models depending on EGFR and RAS mutational status.Phase II study of saracatinib (AZD0530) in patients with previously treated metastatic colorectal cancer.Detection of EML4-ALK in lung adenocarcinoma using pleural effusion with FISH, IHC, and RT-PCR methods.The importance of Src signaling in sarcoma.Enterolactone alters FAK-Src signaling and suppresses migration and invasion of lung cancer cell linesThe next breakthrough in LAM clinical trials may be their design: challenges in design and execution of future LAM clinical trials.What's new in small cell lung cancer - extensive disease? An overview on advances of systemic treatment in 2016.Targeting metastasis.The synergistic role of ATP-dependent drug efflux pump and focal adhesion signaling pathways in vinorelbine resistance in lung cancer.Novel carbonic anhydrase IX-targeted therapy enhances the anti-tumour effects of cisplatin in small cell lung cancer.c-Src activity is differentially required by cancer cell motility modes.Targeting the intracellular signaling "STOP" and "GO" pathways for the treatment of alcohol use disorders.
P2860
Q28076304-77C735F0-0A29-4C58-A8CF-99C8634298B9Q30278774-571E58AE-31A7-4D56-B60E-0F2E48336876Q34480200-A9864490-4384-409B-A3CC-F70648DDCA4AQ35192525-B07A795A-1EB3-4A9A-9511-677F0003C17FQ35802929-0AB45403-91D6-4625-916D-4EF2A2AA8176Q36244710-FE8CEB2C-F765-4F5E-A998-46D80D95B75BQ38372196-8F39C7B4-EEC7-4E65-83E0-1553919976E3Q38661479-DE3718DD-8A59-4AD6-993B-4BF91B63E5F5Q38786658-F5398289-589C-4AAD-A438-96242CAD3729Q47214772-910240F0-3B98-41F0-BC8E-1AFB81A9785AQ47804424-E5FFB8E9-FA54-47DF-BCFC-B9D1044229A3Q49595076-BCF0AE5F-B9D6-4899-9AA0-1B1E9F8DD507Q55133068-FE38D63D-1284-428B-871B-7F81810DA79E
P2860
A phase II trial of the Src-kinase inhibitor saracatinib after four cycles of chemotherapy for patients with extensive stage small cell lung cancer: NCCTG trial N-0621.
description
2014 nî lūn-bûn
@nan
2014 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
A phase II trial of the Src-ki ...... ng cancer: NCCTG trial N-0621.
@ast
A phase II trial of the Src-ki ...... ng cancer: NCCTG trial N-0621.
@en
type
label
A phase II trial of the Src-ki ...... ng cancer: NCCTG trial N-0621.
@ast
A phase II trial of the Src-ki ...... ng cancer: NCCTG trial N-0621.
@en
prefLabel
A phase II trial of the Src-ki ...... ng cancer: NCCTG trial N-0621.
@ast
A phase II trial of the Src-ki ...... ng cancer: NCCTG trial N-0621.
@en
P2093
P2860
P921
P1433
P1476
A phase II trial of the Src-ki ...... ng cancer: NCCTG trial N-0621.
@en
P2093
Alex A Adjei
Andrew V Grainger
Garth D Nelson
John Wright
Julian R Molina
Nathan R Foster
Philip J Stella
Preston D Steen
Randolph Marks
Thanyanan Reungwetwattana
P2860
P304
P356
10.1016/J.LUNGCAN.2014.03.004
P577
2014-05-01T00:00:00Z